Mylan is one of the world’s leading global pharmaceutical companies, with a significant and growing presence in India. We have a workforce of approximately 35,000 people, about half of which are based in India. Our broad portfolio includes generic and brand name products in a variety of dosage forms, which are sold in more than 165 countries and territories.
Mylan’s business in India began in 2007 with the acquisition of Matrix Laboratories Limited. The deal transformed Mylan overnight into one the world’s largest manufacturers of active pharmaceutical ingredients (API) and allowed us to vertically integrate the production of our finished dosage form (FDF) medicines.
Today, Mylan has 47 manufacturing facilities, 19 of which are located in India. Those 19 facilities include eight API facilities, six OSD facilities and five Injectables facilities, which manufacture our high quality medicines for markets all over the world. Our manufacturing capabilities in India include a range of dosage forms, such as tablets, capsules and injectables, in a wide variety of therapeutic categories.
Our API businesses provides hiqh-quality APIs to third parties around the world and antiretroviral products for people living with HIV/AIDS. More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world’s HIV+ children – depend on one of our products.
In addition, Mylan has a growing commercial presence domestically. Our current franchises include Critical Care, Hepato Care, HIV Care, Onco Care and Women’s Health Care.
Our presence in India goes beyond manufacturing, sales and marketing. Hyderabad is home to one of Mylan’s two global R&D centers of excellence . The center has extensive experience working with health authorities from multiple countries. It also is fully integrated with the company’s global R&D function, creating a unique and efficient, ‘round-the-clock research, development, clinical and regulatory capability.